Modality
Radioligand
MOA
CFTRmod
Target
GPRC5D
Pathway
Notch
PSPCRC
Development Pipeline
Preclinical
~Sep 2023
→ ~Dec 2024
Phase 1
Mar 2025
→ Sep 2029
Phase 1Current
NCT05200755
2,171 pts·CRC
2025-03→2029-09·Terminated
2,171 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-033.4y awayPh2 Data· CRC
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2029-09-03 · 3.4y away
CRC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05200755 | Phase 1/2 | CRC | Terminated | 2171 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |